Gene · 9582
Papers1,875
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,875
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Anelloviruses: From General Biology to Their Role as Biomarkers of Immune Competence in HIV Infection. | Viruses | 2026 | 41754578 | PubTator, text mining | PubMed |
| Genomic Instability and Adaptive Evolution Induced by RFA Insufficiency in Saccharomyces cerevisiae. | Curr Issues Mol Biol | 2026 | 41751421 | PubTator, text mining | PubMed |
| Alpha-1B Glycoprotein Is a Novel Hepatocyte-Derived Host Factor Associated with In Vitro Inhibition of HBV Replication and Hepatocellular Carcinoma Progression. | Cancers (Basel) | 2026 | 41749914 | PubTator, text mining | PubMed |
| Hypoxia-mimicked mitochondrial stress triggers APOBEC3A-mediated DNA damage via non-canonical innate immune activation. | NAR Mol Med | 2026 | 41737027 | PubTator, text mining | PubMed |
| hnRNPA2B1 induces HBV cccDNA degradation by recruiting APOBEC3B. | Nucleic Acids Res | 2026 | 41736548 | PubTator, text mining | PubMed |
| HAMMER: Hairpin-based APOBEC3A-mediated mRNA editing reporter. | bioRxiv | 2026 | 41727079 | PubTator, text mining | PubMed |
| APOBEC3A is the predominant global editor of cytosines in human mRNAs and in single-strand RNA viruses. | bioRxiv | 2026 | 41726872 | PubTator, text mining | PubMed |
| R-loop editing by DNA cytosine deaminase APOBEC3B modulates the activity of oestrogen receptor enhancers. | Nat Commun | 2026 | 41702955 | PubTator, text mining | PubMed |
| Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. | Br J Cancer | 2026 | 41699262 | PubTator, text mining | PubMed |
| Mus musculus papillomavirus MmuPV1 resists restriction by human APOBEC3B. | J Virol | 2026 | 41670371 | PubTator, text mining | PubMed |
| Insertional activity of human Alu and L1 retrotransposons is associated with DNA repair pathways and genome instability in cancer. | Comput Biol Med | 2026 | 41655478 | PubTator, text mining | PubMed |
| Effects of thymidylate synthase inhibitors differ in genomic uracilation and mutagenic potential. | Life Sci Alliance | 2026 | 41651672 | PubTator, text mining | PubMed |
| Integrated metabolome and transcriptome analysis reveals ferroptosis involvement in cisplatin resistance of esophageal squamous cancer cell. | Comput Struct Biotechnol J | 2026 | 41608406 | PubTator, text mining | PubMed |
| A system-level metastable model of cancer evolution: integrating replication stress, cell cycle deregulation and chromosomal instability. | Ann Med | 2026 | 41606986 | PubTator, text mining | PubMed |
| MPXV RNA-seq data provide evidence for protection of viral transcripts from APOBEC3 editing. | J Virol | 2026 | 41589909 | PubTator, text mining | PubMed |
| APOBEC3B/ASF1B-TGF-β signaling axis promotes epithelial-mesenchymal transition in HPV-positive oropharyngeal cancer. | J Dent Sci | 2026 | 41585149 | PubTator, text mining | PubMed |
| Guardian ubiquitin E3 ligases target cancer-associated APOBEC3 deaminases for degradation to promote human genome integrity. | Nat Commun | 2026 | 41554709 | Swiss-Prot, curated | PubMed |
| Machine Learning-Driven Identification and In Vitro Validation of the APOBEC3B-ANLN Regulatory Axis in Adrenocortical Carcinoma. | Endocrine | 2026 | 41540175 | PubTator, text mining | PubMed |
| APOBEC3B enhances the efficacy of PARP inhibitors in elimination of ovarian cancer stem cell. | Sci Rep | 2026 | 41535339 | PubTator, text mining | PubMed |
| APOBEC3B-driven mutations negatively regulated by P53 promote tumor progression and immunosuppressive microenvironment in prostate cancer. | Mol Cell Biochem | 2026 | 41385179 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9582/papers?page=2